Zymeworks adds a new lab for fast-grow­ing R&D work; No­var­tis con­sid­ers a spin­off for Al­con

  • Fast-grow­ing Zymeworks has added a new, 10,000-square-foot lab in Van­cou­ver to ac­co­mo­date its re­search staff. “Zymeworks’ new lab is an in­vest­ment in our fu­ture. It will en­able us to per­form our own in­ter­nal re­search and de­vel­op­ment in a ful­ly in­te­grat­ed man­ner,” said CEO Ali Tehrani. “As the Zymeworks fam­i­ly con­tin­ues to grow, so do our re­quire­ments, and the ca­pa­bil­i­ties our new lab pro­vides demon­strate our com­mit­ment to ef­fi­cient­ly ad­vance and ex­pand our ther­a­peu­tic pipeline.”
  • As No­var­tis was bull­ish­ly up­ping its fore­cast on CAR-T, ex­ecs were be­ing forced to ex­plain some weak fi­nan­cials for 2016. The com­pa­ny is now mulling a pos­si­ble spin­off of a strug­gling Al­con, re­ports the Fi­nan­cial Times. And it’s set­ting up a $5 bil­lion buy back to help pla­cate in­vestors as it tries to wres­tle out of its predica­ment.
  • Ann Ar­bor, MI-based Es­pe­ri­on Ther­a­peu­tics $ES­PR has com­plet­ed en­roll­ment in their piv­otal Phase III long-term safe­ty and tol­er­a­bil­i­ty study of be­mpe­doic acid.
  • The FDA has OK’d Adapt Phar­ma’s Nar­can Nasal Spray as a 2mg for­mu­la­tion for the emer­gency treat­ment of known or sus­pect­ed opi­oid over­dose.
Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.